Full Text View
Tabular View
Study Results
Related Studies
Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)
This study has been terminated.
( Terminated early due to low enrollment. )
Study NCT01340573   Information provided by Schering-Plough

First Received on November 18, 2010.   Last Updated on December 22, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis C
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
PegIntron Pen
Ribavirin
Additional drug interventions recognized in this trial
Interferons
Peginterferon alfa-2b
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Schering-Plough


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services